April 17 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N
* Receives Health Canada approval of Darzalex (daratumumab) by priority review for patients with multiple myeloma who have had at least one prior therapy
* Janssen Inc - data from two Phase 3 studies supported new approval of darzalex
* Janssen Inc - due to "high" unmet medical need for multiple myeloma patients, darzalex was granted priority review by Health Canada for submission Source text for Eikon: ID:nCNWlJSxga Further company coverage: JNJ.N